International Journal of Clinical Oncology最新文献

{"title":"A multicenter prospective observational study for health assessment questionnaires EQ-5D-5L and G8 in unresectable advanced pancreatic cancer treated with first-line gemcitabine plus nab-paclitaxel therapy.","authors":"Kaori Hino, Tomohiro Nishina, Mitsuhito Koizumi, Kaori Marui, Masahito Kokubu, Yuki Numata, Yoshiki Imamura, Kozue Kanemitsu-Okada, Toru Otsuru, Taira Kuroda, Yoshinori Ohno, Akinori Asagi, Hideki Miyata, Tomoyuki Yokota, Teru Kumagi, Ichinosuke Hyodo, Yoshio Ikeda, Yoichi Hiasa","doi":"10.1007/s10147-025-02717-1","DOIUrl":"10.1007/s10147-025-02717-1","url":null,"abstract":"<p><strong>Background: </strong>In chemotherapy for unresectable advanced pancreatic cancer (UPC), the clinical utility of pre-treatment health assessment questionnaires, EuroQoL 5-Dimension 5-Level (EQ-5D-5L) and G8, is unknown. This study aimed to fill this gap.</p><p><strong>Methods: </strong>This multicenter, prospective, observational study investigated the association of EQ-5D-5L and G8 with the clinical outcomes of first-line gemcitabine plus nab-paclitaxel (GnP) for UPC. Differences in survival were analyzed using the log-rank test, and multivariate analyses were performed using the Cox proportional hazards model.</p><p><strong>Results: </strong>Between April 2022 and September 2023, 60 patients were enrolled, and their data were analyzed. When patients were classified into two groups using the median EQ-5D-5L utility value (0.824), progression-free survival (PFS) and overall survival (OS) were significantly longer in patients with high EQ-5D-5L utility values than in those with low utility values (median PFS 7.0 vs. 4.7 months, P < 0.01; median OS 12 vs. 8.0 months, P = 0.023). Such differences were not observed in the EQ-5D-5L Visual Analog Scale or G8 scores. There was no association between the occurrence of severe adverse events and EQ-5D-5L or G8 scores. Multivariate analyses showed that high EQ-5D-5L utility value (≥ 0.824), high albumin (≥ 3.8 g/dl), and low carcinoembryonic antigen (CEA) (< 5.4 ng/mL) were preferable independent efficacy predictors for PFS and also independent prognostic factors for OS.</p><p><strong>Conclusion: </strong>Pre-treatment EQ-5D-5L utility value, along with albumin and CEA, was an independent efficacy predictor and prognostic factor in patients with UPC treated with first-line GnP. Their usefulness should be validated in future studies.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"738-748"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human epidermal growth factor receptor 3 expression in patients with epithelial ovarian cancer: a potential target for ovarian mucinous and clear cell carcinoma.","authors":"Sho Sato, Daisuke Shintani, Yuki Kaneda, Ryuichi Nakamura, Tomomi Katoh, Mitsutake Yano, Mieko Hanaoka, Shigehiro Yagishita, Masanori Yasuda, Motoko Nagata, Kosei Hasegawa","doi":"10.1007/s10147-024-02658-1","DOIUrl":"10.1007/s10147-024-02658-1","url":null,"abstract":"<p><strong>Background: </strong>Human epidermal growth factor receptor 3 (HER3), a tyrosine kinase belonging to the HER family, is a known target for cancer therapy; recently, an anti-HER3 antibody-drug conjugate (ADC) is developing. To understand HER3 expression in epithelial ovarian cancer (EOC), this study was conducted.</p><p><strong>Methods: </strong>We investigated the expression of HER3 in 202 patients with EOC using immunohistochemistry (IHC), and the association between HER3 expression, clinicopathological features, prognosis, and treatment timing.</p><p><strong>Results: </strong>Of all the cases, 55.4% had a HER3 IHC score ≥ 1 + . In particular, 78.0% of the patients with clear cell carcinoma (CCC) and 87.9% of the patients with mucinous carcinoma (MC) had a HER3 IHC score ≥ 1 + . Regarding clinicopathological features, early disease stage, feasibility of primary debulking surgery, no residual tumor, and low CA125 levels were more frequently observed in patients with a HER3 IHC score ≥ 1 + . Furthermore, a HER3 no-expression showed a significant association with a relatively short progression-free survival (PFS). And, for patients with mucinous carcinoma, those with a HER3 IHC score ≥ 1 + had poorer PFS and overall survival than those with a HER3 no-expression (no statistically significant difference). In addition, we analyzed HER3 expression at primary tumor and recurrence tumor in same patients. Thus, we observed the HER3 IHC score tended to change from 0 to ≥ 1 + in recurrence cases compared with primary cases.</p><p><strong>Conclusions: </strong>These observations suggested that patients with MC, CCC and recurrence of all histological type may potentially benefit from future clinical trials of HER3-directed therapies.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"805-813"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of early tumor shrinkage and depth of response in patients with BRAF V600E-mutant metastatic colorectal cancer.","authors":"Shohei Udagawa, Hiroki Osumi, Akira Ooki, Keitaro Shimozaki, Takeru Wakatsuki, Shota Fukuoka, Koichiro Yoshino, Mikako Tamba, Mariko Ogura, Keisho Chin, Kensei Yamaguchi, Eiji Shinozaki","doi":"10.1007/s10147-024-02686-x","DOIUrl":"10.1007/s10147-024-02686-x","url":null,"abstract":"<p><strong>Background: </strong>Early tumor shrinkage (ETS) and depth of response (DpR) are early indicators of survival in patients with metastatic colorectal cancer (mCRC) undergoing anti-epidermal growth factor receptor monoclonal antibody treatment. However, their relevance in v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E mutant (MT) mCRC remains unclear. In this study, we evaluate the association between ETS/DpR and clinical outcomes in BRAF V600E MT mCRC.</p><p><strong>Patients and methods: </strong>Patients with mCRC who were diagnosed with BRAF V600E MT and treated with first-line chemotherapy between June 2011 and March 2023 at a single cancer institute were enrolled. The association between ETS/DpR and clinical outcomes in patients with at least one target lesion was assessed. The cutoff value for ETS and DpR was set at 20% and 25%. Multivariate analysis of factors affecting progression-free survival (PFS) and overall survival (OS) was conducted.</p><p><strong>Results: </strong>In total, 54 patients with BRAF V600E MT mCRC exhibited at least one target lesion. Patients with ETS and DpR were 24 (44.4%) and 27 (50%), respectively. Moreover, median PFS and OS were 7.5 and 17.1 months, respectively. Patients with ETS exhibited longer PFS and tended toward longer OS than those without ETS. Similarly, patients with DpR exhibited longer PFS and OS than those without DpR. Multivariate analysis confirmed a significant association between DpR and longer PFS and OS.</p><p><strong>Conclusion: </strong>ETS and DpR could serve as early surrogate markers of clinical outcomes in patients with BRAF V600E MT mCRC treated with first-line chemotherapy.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"718-727"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-marketing surveillance of encorafenib in combination with binimetinib in Japanese patients with BRAF-mutant melanoma.","authors":"Naoya Yamazaki, Hidenori Sakata, Osamu Iida, Teruaki Katayama, Hisashi Uhara","doi":"10.1007/s10147-025-02693-6","DOIUrl":"10.1007/s10147-025-02693-6","url":null,"abstract":"<p><strong>Background: </strong>A BRAF inhibitor, encorafenib, combined with a MEK inhibitor, binimetinib, was approved in Japan in early 2019 for the treatment of BRAF V600-mutant, unresectable malignant melanoma based on results of the global phase III trial, COLUMBUS, conducted in various countries including Japan. This post-marketing surveillance (PMS) assessed the combination in real-world clinical practice in Japan.</p><p><strong>Methods: </strong>We performed a prospective, multicentre, 12-month PMS of the safety and effectiveness of encorafenib plus binimetinib for radically unresectable, BRAF-mutant malignant melanoma in Japan.</p><p><strong>Results: </strong>Among 174 survey forms collected from 85 centres between February 2019 and August 2020, 172 were included for safety and effectiveness analysis. Patients (male [52.3%], median age 62.0 years) had Eastern Cooperative Oncology Group Performance Status 0 or 1 (91.8%) and comorbidities (55.2%). Respective encorafenib and binimetinib median dosages were 450 mg/day and 90 mg/day; median treatment duration, 24.1 and 24.2 weeks, and discontinuation, 71.5% for each, primarily for disease progression (56.9%) and adverse drug reactions (ADRs, 38.2%). Safety assessment ADRs occurred in 99 patients (57.6%), including eye disorders (40.7%), hepatic dysfunction (20.3%), rhabdomyolysis (4.7%), haemorrhage (2.3%), palmar-plantar erythrodysaesthesia syndrome (1.7%), and hypertension (1.7%); 19.8% were grade ≥ 3, none were grade 5, most resolved with/without treatment modification. At 12 months, the objective response rate was 48.8% (95% CI 41.2, 56.6; complete [19.2%], partial [29.7%]), overall survival was 40.1%.</p><p><strong>Conclusion: </strong>The safety and effectiveness of encorafenib plus binimetinib in Japanese patients with BRAF-mutant malignant melanoma were similar to data reported in COLUMBUS; no new safety concerns were identified.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"814-823"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11946937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of HPV status on oropharyngeal cancer detection via gastrointestinal endoscopy: a retrospective study.","authors":"Sayoko Tayama, Hideaki Miyamoto, Kotaro Waki, Munenori Honda, Kenshi Matsuno, Akira Yamasaki, Ryosuke Gushima, Katsuya Nagaoka, Hideaki Naoe, Masanori Imuta, Fumi Kawakami, Yoshihiro Komohara, Satoru Miyamaru, Daizo Murakami, Yorihisa Orita, Yasuhito Tanaka","doi":"10.1007/s10147-025-02692-7","DOIUrl":"10.1007/s10147-025-02692-7","url":null,"abstract":"<p><strong>Background: </strong>Gastrointestinal endoscopy (GIE) performed by gastroenterologists is essential for the early detection of pharyngeal cancer. Human papillomavirus (HPV) is a significant cause of oropharyngeal squamous cell carcinoma (OPSCC). However, the prevalence of HPV-related OPSCC detected by GIE remains unclear.</p><p><strong>Aim: </strong>This study aims to evaluate the differences in detection rates, patient characteristics, and treatment approaches between HPV-positive and HPV-negative OPSCCs, with a focus on the role of GIE in early diagnosis.</p><p><strong>Methods: </strong>We retrospectively analyzed 207 OPSCCs from 2018 to 2022, where HPV infection was diagnosed by p16 immunohistochemistry. We compared detection modalities and evaluated the proportion of lesions detected by GIE in both p16-positive and p16-negative cases.</p><p><strong>Results: </strong>Out of the 207 patients, 92 (44.4%) were p16-positive. p16-positive cases had significantly lower rates of alcohol use, smoking, and history of esophageal or head/neck squamous cell carcinoma (all p < 0.001). Only 4.3% of p16-positive cases were detected by GIE, compared to 44.3% of p16-negative cases (p < 0.001). In addition, p16-positive patients were often diagnosed at advanced stages and underwent transoral resection less frequently (2.2% vs. 31.3%, p < 0.001). In cT1 cases, GIE and laryngoscopy revealed that p16-positive lesions were typically protruding and white to normal-colored, while p16-negative lesions were predominantly flat and erythematous.</p><p><strong>Conclusions: </strong>HPV-related OPSCC cases are rarely detected by GIE, and few cases are treated with minimally invasive transoral resection. These findings highlight the need for enhanced detection strategies for HPV-positive OPSCC.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"696-704"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143492068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune checkpoint inhibitors in the treatment of pleural mesothelioma: insights from real-world data.","authors":"Masatoshi Kanayama, Takehiko Manabe, Katsuma Yoshimatsu, Rintaro Oyama, Hiroki Matsumiya, Masataka Mori, Masaru Takenaka, Koji Kuroda, Fumihiro Tanaka","doi":"10.1007/s10147-025-02706-4","DOIUrl":"10.1007/s10147-025-02706-4","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) have recently emerged as a promising strategy for the treatment of pleural mesothelioma (PM).</p><p><strong>Methods: </strong>This retrospective study evaluated treatment efficacy and safety in Japanese patients with PM treated with nivolumab and ipilimumab (N + I group: 41 patients) as first-line therapy and nivolumab monotherapy (N group: 33 patients) as second- or later-line treatment.</p><p><strong>Results: </strong>The median overall survival (OS) and progression-free survival (PFS) were not reached and 10.4 months in the N + I group, and 8.6 months and 3.5 months in the N group, respectively. Treatment-related adverse events (TRAEs) of any grade occurred in 68.3% of the N + I group and 72.7% of the N group, with grade 3-4 TRAEs in 19.5% and 12.1% of patients, respectively. Patients with an ECOG PS 0-1 had significantly better OS and PFS in both treatment groups (p < 0.001). In the N + I group, OS was significantly better in patients with TRAEs (p = 0.020) and in those with the epithelioid subtype (p = 0.047), although PFS was not significantly different (p = 0.138 and p = 0.154, respectively). In the N group, both OS (p = 0.007) and PFS (p = 0.048) were significantly longer in patients with TRAEs.</p><p><strong>Conclusion: </strong>This study provides valuable real-world clinical evidence of the efficacy and safety of nivolumab plus ipilimumab and nivolumab monotherapy in Japanese patients with PM. These results support the use of ICIs as a viable treatment option for advanced or relapsed disease.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"705-717"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survey of healthcare professionals' awareness of appearance care for Japanese cancer patients and their institutions' appearance care systems: report from the Japan Society of Clinical Oncology.","authors":"Shiho Kuji, Keiko Nozawa, Shoko Toma, Harue Arao, Shigeru Imoto, Hiroaki Kajiyama, Atsuko Kitano, Yasuhiro Kodera, Ryuta Saito, Rika Sakai, Akinobu Taketomi, Robert Nakayama, Eiso Hiyama, Manabu Futamura, Motohiro Matsui, Masahito Yonemura, Mototsugu Oya, Nao Suzuki","doi":"10.1007/s10147-024-02685-y","DOIUrl":"10.1007/s10147-024-02685-y","url":null,"abstract":"<p><strong>Background: </strong>Appearance care enables cancer patients to maintain social connections during treatment, but it remains an unmet need in Japan. We surveyed healthcare professionals in Japan to collect information on their awareness of appearance care and their institutions' appearance care systems.</p><p><strong>Methods: </strong>From November 1 to December 13, 2022, we performed an online survey of 16,838 members of the Japan Society of Clinical Oncology.</p><p><strong>Results: </strong>We received responses from 807 members (671(83%) physicians; 65(8%) pharmacists; 45(6%) nurses; 22(3%) dentists; and 4(0.5%) others), 72% of whom were men and 28%, women. Among respondents, 93% (n = 749//807) had been asked by patients about appearance care, and 46% (n = 318/693) of the physicians and dentists had refused to perform treatment or changed it because of its effects on physical appearance. Only 59% (n = 410) of physicians and dentists were familiar with the term appearance care, but 100% (n = 45) of nurses and 97% (n = 63) of pharmacists were. Among all respondents, 26% reported that their institution had a specialized department and specific personnel for appearance care. In some cases, physicians and dentists had difficulty communicating correct information to patients, and other healthcare professionals compensated for this deficit.</p><p><strong>Conclusion: </strong>The survey revealed that physicians have low awareness of appearance care. It was suggested that communication and a team approach between physicians and other healthcare professionals is recommended. Each medical facility may be encouraged to establish a sustainable system for providing information on appearance care in that patients or medical personnel themselves can easily consult. Activities are also needed to raise awareness about appearance care among physicians.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"655-665"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal assessment of bone mineral density in prostate cancer patients: comparing metastatic and non-metastatic regions.","authors":"Takuto Hara, Hanako Nishimoto, Tomoaki Terakawa, Yasuyoshi Okamura, Yukari Bando, Hideto Ueki, Kotaro Suzuki, Yoji Hyodo, Jun Teishima, Koji Chiba, Ryosuke Kuroda, Hideaki Miyake","doi":"10.1007/s10147-025-02711-7","DOIUrl":"10.1007/s10147-025-02711-7","url":null,"abstract":"<p><strong>Objectives: </strong>Prostate cancer patients receiving androgen deprivation therapy (ADT) have increased risks of decreased bone mineral density (BMD). However, there are no established guidelines for assessing BMD in patients with bone metastases. The aim of this study was to assess the effects of ADT on bone health by comparing longitudinal changes in BMD between prostate cancer patients with and without bone metastases.</p><p><strong>Methods: </strong>A single-center observational study was conducted from February 2020 to January 2023 at Kobe University Hospital. BMD at the lumbar vertebrae, total hip, and femoral neck was measured at baseline, 6, and 12 months using dual-energy X-ray absorptiometry. Bones were classified into Metastatic Site (with metastases), Non-metastatic Sites (from patients with bone metastases), and Control (patients without metastases) groups. All patients received luteinizing hormone-releasing hormone antagonists or agonists plus oral ARSI or bicalutamide for 1 year.</p><p><strong>Results: </strong>Among the 78 patients, 35, 110, and 245 bones were classified into the Metastatic Site group, Non-metastatic Sites group, and Control group, respectively. The Metastatic Site group exhibited significantly higher T-scores compared with the other groups (P < 0.001). Repeated measures analysis revealed a statistically significant reduction in T-scores over time across all groups (P < 0.001). However, no significant interaction was observed between group classification and time (P = 0.817).</p><p><strong>Conclusion: </strong>The present study demonstrates that BMD changes at non-metastatic sites in patients with bone metastases are similar to those in patients without metastases. Monitoring BMD at non-metastatic sites may provide valuable insights into ADT's effects on bone health in prostate cancer patients.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"797-804"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11946959/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical utility of comprehensive genomic profiling for advanced pancreatic cancer: insights from real-world data analysis.","authors":"Eiichiro So, Hideyuki Hayashi, Keitaro Shimozaki, Sara Horie, Shotaro Kishimoto, Akihiko Chida, Yuki Saito, Kai Tsugaru, Kenro Hirata, Shigeki Tanishima, Hiroshi Nishihara, Takanori Kanai, Yasuo Hamamoto","doi":"10.1007/s10147-025-02713-5","DOIUrl":"10.1007/s10147-025-02713-5","url":null,"abstract":"<p><strong>Background: </strong>Precision medicine is a promising therapeutic strategy for pancreatic cancer. However, only a few patients are eligible for genotype-matched treatments because of the low detection rate of actionable genomic alterations, and the clinical application of comprehensive genomic profiling (CGP) in pancreatic cancer has not been completely investigated. CGP provides considerable information, including the prognosis and eligibility of patients for genotype-matched treatments, which can guide physicians' treatment strategies. This study aimed to investigate the contribution of CGP to patient outcomes.</p><p><strong>Methods: </strong>This single-center retrospective cohort study enrolled patients with recurrent or metastatic pancreatic cancer with adenocarcinoma or adenosquamous carcinoma who underwent systemic chemotherapy between April 2018 and April 2022. We reviewed the medical records for patient characteristics, survival, and genomic information. We compared overall survival (OS) between patients who received CGP (CGP group) and those who did not (non-CGP group).</p><p><strong>Results: </strong>Of 111 eligible patients, 59 underwent CGP. Median OS was significantly longer in the CGP than the non-CGP group (25.2 vs. 11.8 months; hazard ratio, 0.49; P = 0.0013). Six patients (10.2%) underwent genotype-matched treatments, with a median OS of 35.5 months, compared to 17.0 months for those who did not. The CGP group demonstrated a higher transition rate to subsequent chemotherapy than did the non-CGP group (76.3% vs. 48.1%, P = 0.0030).</p><p><strong>Conclusions: </strong>OS was prolonged in patients with pancreatic cancer who underwent CGP, probably due to its influence on physicians' treatment strategies. These findings highlight the importance of the proactive and timely implementation of CGP in patients with pancreatic cancer.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"728-737"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortium.","authors":"Taizo Uchimoto, Kengo Iwatsuki, Kazumasa Komura, Wataru Fukuokaya, Takahiro Adachi, Yosuke Hirasawa, Takeshi Hashimoto, Atsuhiko Yoshizawa, Masanobu Saruta, Mamoru Hashimoto, Takafumi Minami, Yutaka Yamamoto, Shogo Yamazaki, Tomoaki Takai, Moritoshi Sakamoto, Yuki Nakajima, Kazuki Nishimura, Ryoichi Maenosono, Takuya Tsujino, Ko Nakamura, Tatsuo Fukushima, Kyosuke Nishio, Yuki Yoshikawa, Shutaro Yamamoto, Kosuke Iwatani, Fumihiko Urabe, Keiichiro Mori, Takafumi Yanagisawa, Shunsuke Tsuduki, Kiyoshi Takahara, Kazutoshi Fujita, Takahiro Kimura, Yoshio Ohno, Ryoichi Shiroki, Haruhito Azuma","doi":"10.1007/s10147-025-02709-1","DOIUrl":"10.1007/s10147-025-02709-1","url":null,"abstract":"<p><strong>Background: </strong>Enfortumab vedotin (EV), an antibody-drug conjugate (ADC) targeting Nectin-4, has been available as standard care for metastatic urothelial carcinoma (mUC) patients who have progressed after platinum-based chemotherapy and checkpoint inhibitors (CPIs). However, the association between body mass index (BMI) and clinical outcomes for EV remains unknown.</p><p><strong>Methods: </strong>We analyzed the records of 123 mUC patients who received EV. The cohort was divided into low BMI (< 22, n = 65) and high BMI (≥ 22, n = 58) groups. Propensity score matching was performed to reduce clinical bias between the two groups.</p><p><strong>Results: </strong>In the total cohort (n = 123), the objective response rate (ORR) and disease control rate (DCR) were 46% and 68%, respectively. The ORR was significantly higher in the higher BMI group (62%, n = 58) compared to the lower BMI group (32%, n = 65). Among the pair-matched cohort (n = 100), despite reducing potential bias, the ORR remained significantly higher in the higher BMI group than in the lower BMI group (64% vs. 32%, p = 0.002). Both overall survival (OS) and radiographic progression-free survival (r-PFS) were longer in the higher BMI group compared to the lower BMI group (median OS: not reached vs. 8 months, p = 0.035; median r-PFS: 10 vs. 4 months, p < 0.001). On multivariate analyses, a higher BMI (≥ 22) was an independent predictor for achieving objective response and favorable OS in mUC patients treated with EV.</p><p><strong>Conclusions: </strong>The findings of this study suggest a potential association between high BMI and improved tumor response to EV in mUC patients with disease progression after platinum-based chemotherapy and CPIs.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"761-769"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}